logo
Plus   Neg
Share
Email

Vertex: EC Approves ORKAMBI To Treat Children With CF Aged 2 To 5 Years Old

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that the European Commission has granted approval of the label extension for ORKAMBI (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis or CF aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease.

The label update is based on data from a Phase 3 open-label safety study in 60 patients that showed treatment with lumacaftor/ivacaftor was generally well tolerated for 24 weeks, with a safety profile in these pediatric patients generally consistent with that in patients aged 6 years and older.

Lumacaftor/ivacaftor is already approved in the EU for the treatment of CF in patients aged 6 and older who have two copies of the F508del mutation.

Cystic fibrosis is a rare, life-shortening genetic disease affecting approximately 75,000 people in North America, Europe and Australia.

Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex, said, "Today's approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF. By treating the underlying cause of disease early, we can potentially modify its course and offer patients the chance of improved outcomes."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Monsanto on Thursday pleaded guilty to illegally using a banned pesticide known as Penncap-M on research crops at one of its facilities on the Hawaiian island of Maui. The agro-chemicals company will pay $10 million for charges that it unlawfully stored the banned pesticide, which had to be managed as an acute hazardous waste. The banned pesticide is specifically methyl parathion. Anti-aging skin care products, beauty serum ingredients and essential oils provider Resurrectionbeauty issued a recall for about 270 units of wintergreen essential oil due to risk of poisoning for young children if they swallow it. However, the company has not received reports of any incidents or injuries so far. The product contains the substance methyl salicylate. Microsoft has delayed the worldwide launch of its Surface Earbuds till Spring 2020. The $249 wireless earbuds were originally expected to launch this year. The delay is a setback in Microsoft's attempt to compete with Apple's latest earbuds, AirPods Pro, which has a new design and features active noise cancellation.
RELATED NEWS
Follow RTT
>